Filing Details

Accession Number:
0001127602-10-007291
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-03-03 12:00:00
Reporting Period:
2010-03-01
Filing Date:
2010-03-03
Accepted Time:
2010-03-03 19:05:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
729922 Osi Pharmaceuticals Inc OSIP In Vitro & In Vivo Diagnostic Substances (2835) 133159796
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1314821 Lundemose Anker Md, Ph.d, Dsc C/O Osi Pharmaceuticals, Inc.
41 Pinelawn Road
New York NY 11747
Evp, Corp. Dev & Strategic Pln No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-03-01 15,200 $35.10 46,823 No 4 M Direct
Common Stock Acquisiton 2010-03-01 13,000 $29.77 59,823 No 4 M Direct
Common Stock Disposition 2010-03-01 29,200 $55.20 30,623 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2010-03-01 15,200 $0.00 15,200 $35.10
Common Stock Stock Option (Right to Buy) Disposition 2010-03-01 13,000 $0.00 13,000 $29.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2005-02-11 2014-02-10 No 4 M Direct
5,000 2007-06-13 2013-06-12 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a Rule 10b5-1 trading plan adopted on November 3, 2009.
  2. The price reported represents the weightedaverage sales price of shares sold in multiple transactions at prices ranging from $55.15 to $55.32 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. One third of the stock options became exercisable one year after the date of the grant and the remainder vested ratably on a monthly basis over the succeeding 24 months.
  4. 25% of the option became exercisable one year after the date of grant and the remainder vests ratably on an annual basis over the succeeding 3 years.
  5. Includes only options with the same termination date.